As we approach the final rankings of the season, it is clear that the committee has shown a strong bias towards Ohio State. Despite their somewhat questionable resume, the Buckeyes continue to be ranked higher than other deserving teams. Their strength of record is certainly impressive, but when we evaluate their wins, it becomes evident
0 Comments
Meta, the company behind social networking platforms like Facebook and Instagram, recently announced its new policies on political ads. In an effort to address concerns regarding misinformation and misleading content, Meta will now require advertisers to disclose their use of artificial intelligence (AI) to alter images and videos in certain political ads. This move by
0 Comments
Disney CEO Bob Iger recently addressed employees during a town hall meeting, expressing his excitement for the future of the company. After a year focused on fixing various aspects of the business, Iger is now looking forward to a period of building and growth. In this article, we will explore Disney’s plans for expansion, the
0 Comments
Amazon has announced that it experienced “record-breaking” sales leading up to Cyber Monday, as consumers sought discounts amidst rising inflation. The company declared that this year’s holiday shopping event, which took place from November 17th to Cyber Monday, marked its “biggest ever” compared to the same 11-day period in the previous year. While exact sales
0 Comments
In a groundbreaking move, Parmar Entertainment, a fledgling producer-distributor, has recently acquired the global rights to Russell Peters’ highly anticipated comedy special, Act Your Age. The acquisition reportedly came at a staggering seven-figure deal, solidifying the company’s determination to make a significant impact in the streaming space. Recorded live at Abu Dhabi’s renowned Etihad Arena
0 Comments
The International Gynecologic Cancer Society (IGCS) annual meeting recently featured the presentation of updated results from a phase I study on the investigational bispecific antibody ubamatamab (REGN4018). This antibody, when used alone or in combination with the PD-1 inhibitor cemiplimab (Libtayo), demonstrated both safety and activity in patients with recurrent ovarian cancer. In this article,
0 Comments